Targeted therapy for triple-negative breast cancer
10.3760/cma.j.issn.1673-422X.2012.07.012
- VernacularTitle:三阴性乳腺癌的靶向治疗研究进展
- Author:
Ronghui LI
;
Caiwen DU
;
Guojun ZHANG
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Poly(ADP-ribose)polymerases;
Receptor;
epidermal growth factor;
Receptor;
CXCR4 inhibitor
- From:
Journal of International Oncology
2012;39(7):519-522
- CountryChina
- Language:Chinese
-
Abstract:
Triple-negative breast cancer(TNBC)is a special subtype of breast cancer which is invalid to endocrine therapy.Anti-Her2 targeted therapies such as herceptin and lapatinib are not suitable to TNBC.At present,conventional chemotherapy is the only way for the medical therapy of TNBC.Thus,searching for novel therapeutic agents for TNBC is one of hot researches of breast cancer.New targeted therapy drugs such as PARP-1 inhibitors,EGFR inhibitors,CXCR4 inhibitors,anti-angiogenesis drugs,Src tyrosine kinase inhibitor,and mTOR inhibitor are being researched.
